cept Therapeutics rporated(CORT) - 2024 Q2 - Quarterly Results

MENLO PARK, Calif., (July 29, 2024) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2024. • Increase in 2024 revenue guidance to $640 – $670 million, from $620 – $650 million "Once again, we had a record number of new Korlym® prescribers ...